Most Recent
Japanese pharmaceutical company Astellas Pharma has signed a deal worth up to $2 billion with Melbourne-based start-up Audax Biosciences to secure future rights to develop and commercialise its new cancer treatment.
Construction PRO
Macquarie International Health Clinic has lost the latest chapter in its decades long battle over the proposed development of a private hospital within the precincts of Sydney's Royal Prince Alfred Hospital.
Two law firms will battle for carriage of a shareholder class action against hearing device manufacturer Cochlear, a court has heard.
Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.
Arrotex has secured an exclusive licence to sell Sydney-based biotech Recce Pharmaceuticals’ experimental diabetic foot infection treatment in Australia and New Zealand.
US-based medical device maker OrthAlign has lost its lawsuit alleging Sydney-based surgical technology company Navbit infringed its patent for a technology used to guide the positioning of artificial hip joints during surgery.
Swiss drug companies Actelion and J&J's Janssen-Cilag have brought litigation against three generics makers over their plans to launch cheaper versions of two blood pressure medications.
IP Australia has ruled in favour of supplement maker Nature’s Way, finding that the registration of a Chinese competitor’s ‘Nature’s Bay’ trade mark was likely to cause consumer confusion.
AstraZeneca has attacked generic drugmaker Pharmacor’s challenge to a patent extension for its diabetes drug Forxiga, telling a judge that it hinges on the false notion that the protected IP is limited to a single molecule.
A class action against Johnson & Johnson over allegedly carcinogenic talcum powder still can't say whether it has sued the correct entities and wants the company to sift through 100 years of corporate history to save it from playing "whack-a-mole".